TAK
Takeda Pharmaceutical Company Limited
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+42/100
Last price
18.37
▲ 0.27 (1.49%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
18.10
Day high
18.46
Day low
18.14
Volume
2.47M
Market cap
$58.68B
P/E (TTM)
—
52W range
12.99 – 19.10
Trailing performance
Returnvs SPY
1W
+0.99%
-0.9%
1M
+0.27%
-1.2%
3M
+10.60%
+7.2%
6M
-1.55%
-16.5%
YTD
+17.83%
+3.9%
1Y
+26.25%
+10.5%
3Y
+20.22%
-61.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TAK open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+585.31K
Net buying
Buy transactions
23
1.33M shares
Sell transactions
19
749.34K shares
Net transactions
+42
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
2.24M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 14, 26 | DUPREY LAUREN RUSCKOWSKI Officer |
SELL | 34.53K | $640.28K | Direct |
| Sep 2, 26 | PLUMP ANDREW STEWART Officer and Director |
SELL | 116.19K | $2.15M | Indirect |
| Aug 19, 26 | PLUMP ANDREW STEWART Officer and Director |
SELL | 19.65K | $363.35K | Indirect |
| Aug 18, 26 | GREENWAY NICOLA DEIDRE PETAL Officer |
SELL | 12.98K | $235.12K | Direct |
| Aug 11, 26 | SHANNON ELAINE MARY Officer |
SELL | 20.36K | $357.37K | Direct |
| Aug 10, 26 | DUPREY LAUREN RUSCKOWSKI Officer |
SELL | 47.59K | $813.72K | Direct |
| Aug 10, 26 | PIGNAGNOLI AGOSTI MARCELLO Officer |
SELL | 22.96K | $392.56K | Direct |
| Aug 10, 26 | SHANNON ELAINE MARY Officer |
SELL | 3.98K | $68.02K | Direct |
| Aug 10, 26 | KIM JULIE SO-YOUNG Chief Executive Officer |
SELL | 89.09K | $1.52M | Direct |
| Aug 10, 26 | GREENWAY NICOLA DEIDRE PETAL Officer |
SELL | 34.60K | $605.78K | Direct |
| Aug 10, 26 | GREENWAY NICOLA DEIDRE PETAL Officer |
SELL | 6.77K | $115.83K | Direct |
| Aug 10, 26 | FURNEY NATALIE ANNE MARIE Officer |
SELL | 30.87K | $527.84K | Direct |
| Aug 10, 26 | PACHECO RHONDA JANICE Officer |
SELL | 16.90K | $289.01K | Direct |
| Aug 10, 26 | FARAJALLAH AWNY SAMAAN BOTROS M.D. Officer |
SELL | 14.01K | $239.50K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BITETTI TERESA MARIE |
Officer | 252.01K | Sale |
DUPREY LAUREN RUSCKOWSKI |
Officer | 191.52K | Sale |
FURNEY NATALIE ANNE MARIE |
Officer | 204.30K | Sale |
KIM JULIE SO-YOUNG |
Chief Executive Officer | 391.49K | Sale |
PACHECO RHONDA JANICE |
Officer | 182.51K | Sale |
PIGNAGNOLI AGOSTI MARCELLO |
Officer | 176.98K | Sale |
PLATFORD GILES RICHARD |
Officer | 315.84K | Sale |
PLUMP ANDREW STEWART |
Officer and Director | — | Sale |
RICCI GABRIELE |
Chief Technology Officer | 171.65K | Sale |
WEBER CHRISTOPHE PIERRE |
Chief Executive Officer | 418.80K | Stock Award(Grant) |
Fundamentals
Market cap$58.68B
Enterprise value$5.13T
Revenue (TTM)$4.62T
Gross profit$2.98T
EBITDA$1.25T
Net income$-163.44B
EPS (TTM)$-0.34
Free cash flow$541.44B
Total cash$460.98B
Total debt$5.54T
Book value / share$15.11
Shares outstanding3.19B
Float3.16B
Short % of float0.13%
Dividend yield3.36%
Beta (5Y)0.10
Valuation & profitability ratios
Trailing P/E—
Forward P/E34.66
PEG ratio0.41
Price / sales—
Price / book1.22
EV / revenue1.11
EV / EBITDA4.11
Gross margin64.47%
Operating margin16.45%
Profit margin-3.54%
Return on equity-2.26%
Return on assets2.69%
Debt / equity73.25
Current ratio1.14
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.51T | $4.58T | $4.26T | $4.03T | -1.7% |
| Operating revenue | $4.51T | $4.58T | $4.26T | $4.03T | -1.7% |
| Cost of revenue | $1.57T | $1.58T | $1.43T | $1.24T | -0.5% |
| Gross profit | $2.93T | $3.00T | $2.84T | $2.78T | -2.2% |
| Research & development | $675.92B | $730.23B | $729.92B | $633.33B | -7.4% |
| Selling, general & admin | $1.08T | $1.10T | $1.05T | $997.31B | -1.9% |
| Total operating expense | $2.47T | $2.53T | $2.53T | $2.20T | -2.6% |
| Operating income | $464.45B | $466.37B | $309.90B | $587.81B | -0.4% |
| Net interest income | -$143.77B | -$160.55B | -$140.46B | -$123.39B | +10.5% |
| Pre-tax income | -$142.35B | $175.08B | $52.79B | $375.09B | -181.3% |
| Tax provision | $9.77B | $66.94B | -$91.41B | $58.05B | -85.4% |
| Net income | -$152.39B | $107.93B | $144.07B | $317.02B | -241.2% |
| Net income to common | -$152.39B | $107.93B | $144.07B | $317.02B | -241.2% |
| Basic EPS | 60.88 | 34.18 | 46.05 | 102.15 | +78.1% |
| Diluted EPS | 59.82 | 33.62 | 45.58 | 100.97 | +78.0% |
| EBIT | $5.77B | $312.39B | $172.33B | $492.06B | -98.2% |
| EBITDA | $726.89B | $1.07T | $900.33B | $1.16T | -32.3% |
| Basic shares | 3.15B | 3.16B | 3.13B | 3.10B | -0.2% |
| Diluted shares | 3.21B | 3.21B | 3.16B | 3.14B | -0.2% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $595.05B | $385.11B | $457.80B | $533.53B | +54.5% |
| Cash & short-term investments | $636.94B | $405.59B | $472.89B | $553.70B | +57.0% |
| Accounts receivable | $977.36B | $770.90B | $718.67B | $674.69B | +26.8% |
| Inventory | $1.40T | $1.22T | $1.21T | $986.46B | +14.7% |
| Total current assets | $3.09T | $2.52T | $2.56T | $2.40T | +22.6% |
| Property, plant & equipment | $2.12T | $1.97T | $1.99T | $1.69T | +7.7% |
| Goodwill & intangibles | $9.23T | $8.96T | $9.68T | $9.06T | +3.0% |
| Total assets | $15.51T | $14.25T | $15.11T | $13.96T | +8.9% |
| Total current liabilities | $2.83T | $2.51T | $2.31T | $2.48T | +13.0% |
| Current debt | $512.16B | $548.94B | $367.25B | $339.60B | -6.7% |
| Long-term debt | $4.37T | $3.97T | $4.48T | $4.04T | +10.2% |
| Total debt | $4.88T | $4.52T | $4.84T | $4.38T | +8.1% |
| Total liabilities | $8.08T | $7.31T | $7.83T | $7.60T | +10.5% |
| Retained earnings | $712.38B | $1.19T | $1.39T | $1.54T | -40.0% |
| Shareholder equity | $7.43T | $6.94T | $7.27T | $6.35T | +7.1% |
| Working capital | $258.43B | $14.67B | $245.48B | -$83.98B | +1,661.5% |
| Net tangible assets | -$1.80T | -$2.02T | -$2.41T | -$2.71T | +11.0% |
| Shares issued | 1.59B | 1.59B | 1.58B | 1.58B | +0.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$152.13B | $108.14B | $144.20B | $317.04B | -240.7% |
| Depreciation & amortisation | $721.13B | $761.40B | $728.00B | $664.40B | -5.3% |
| Stock-based compensation | $72.78B | $72.87B | $70.87B | $60.67B | -0.1% |
| Change in working capital | $199.91B | -$59.37B | -$256.00B | -$25.26B | +436.7% |
| Operating cash flow | $1.04T | $1.06T | $716.34B | $977.16B | -1.5% |
| Capital expenditure | -$414.66B | -$379.63B | -$480.73B | -$633.69B | -9.2% |
| Investing cash flow | -$369.14B | -$367.06B | -$463.86B | -$607.10B | -0.6% |
| Share buybacks | -$51.60B | -$51.86B | -$2.33B | -$26.93B | +0.5% |
| Dividends paid | -$311.90B | -$302.50B | -$287.19B | -$279.42B | -3.1% |
| Financing cash flow | -$496.82B | -$751.42B | -$354.42B | -$709.15B | +33.9% |
| Free cash flow | $626.77B | $677.56B | $235.61B | $343.47B | -7.5% |
| End cash position | $595.05B | $385.11B | $457.80B | $533.53B | +54.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.22T | $1.09T | $1.19T | $1.11T | $1.11T | +11.5% |
| Operating revenue | $1.22T | $1.09T | $1.19T | $1.11T | $1.11T | +11.5% |
| Cost of revenue | $406.68B | $405.70B | $401.15B | $380.06B | $384.68B | +0.2% |
| Gross profit | $813.22B | $688.84B | $790.55B | $732.74B | $722.01B | +18.1% |
| Research & development | $167.40B | $195.32B | $175.23B | $161.48B | $143.89B | -14.3% |
| Selling, general & admin | $286.51B | $292.00B | $282.78B | $253.55B | $255.88B | -1.9% |
| Total operating expense | $611.81B | $646.77B | $621.73B | $663.74B | $537.45B | -5.4% |
| Operating income | $201.42B | $42.07B | $168.82B | $69.00B | $184.56B | +378.8% |
| Net interest income | -$39.24B | -$35.88B | -$35.76B | -$38.74B | -$33.40B | -9.4% |
| Pre-tax income | $162.72B | -$455.02B | $133.86B | $28.17B | $150.63B | +135.8% |
| Tax provision | $49.46B | -$86.61B | $30.13B | $39.90B | $26.35B | +157.1% |
| Net income | $113.20B | -$368.47B | $103.64B | -$11.80B | $124.24B | +130.7% |
| Net income to common | $113.20B | -$368.47B | $103.64B | -$11.80B | $124.24B | +130.7% |
| Basic EPS | 35.83 | — | — | — | 39.70 | — |
| Diluted EPS | 35.27 | — | — | — | 39.12 | — |
| EBIT | $226.56B | -$620.82B | $257.49B | $111.31B | $257.79B | +136.5% |
| EBITDA | $337.49B | -$456.95B | $448.13B | $316.47B | $389.43B | +173.9% |
| Basic shares | 3.16B | — | — | — | 3.13B | — |
| Diluted shares | 3.21B | — | — | — | 3.18B | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $460.98B | $595.05B | $654.94B | $681.49B | $350.01B | -22.5% |
| Cash & short-term investments | $527.58B | $636.94B | $761.94B | $739.68B | $419.18B | -17.2% |
| Accounts receivable | $930.38B | $977.36B | $736.46B | $688.96B | $665.63B | -4.8% |
| Inventory | $1.45T | $1.40T | $1.41T | $1.30T | $1.24T | +3.6% |
| Total current assets | $3.15T | $3.09T | $3.12T | $2.92T | $2.51T | +1.9% |
| Property, plant & equipment | $2.14T | $2.12T | $2.08T | $1.98T | $1.96T | +1.0% |
| Goodwill & intangibles | $9.28T | $9.23T | $9.27T | $8.73T | $8.72T | +0.5% |
| Total assets | $15.66T | $15.51T | $15.41T | $14.47T | $14.00T | +1.0% |
| Total current liabilities | $2.76T | $2.83T | $2.61T | $2.14T | $2.17T | -2.4% |
| Current debt | $519.97B | $512.16B | $583.15B | $293.86B | $371.14B | +1.5% |
| Long-term debt | $4.42T | $4.37T | $4.27T | $4.35T | $4.13T | +1.2% |
| Total debt | $4.94T | $4.88T | $4.85T | $4.65T | $4.51T | +1.2% |
| Total liabilities | $8.10T | $8.08T | $7.76T | $7.34T | $7.14T | +0.3% |
| Retained earnings | $667.01B | $712.38B | $1.10T | $1.15T | $1.16T | -6.4% |
| Shareholder equity | $7.56T | $7.43T | $7.64T | $7.13T | $6.87T | +1.7% |
| Working capital | $385.72B | $258.43B | $506.26B | $780.97B | $343.54B | +49.3% |
| Net tangible assets | -$1.72T | -$1.80T | -$1.63T | -$1.60T | -$1.85T | +4.4% |
| Shares issued | 1.59B | 1.59B | 1.59B | 1.59B | 1.59B | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | — | -$368.41B | $103.73B | -$11.73B | $124.28B | -$103.10B | — |
| Depreciation & amortisation | — | $163.87B | $190.64B | $184.98B | $181.64B | $189.77B | — |
| Stock-based compensation | — | $19.71B | $17.80B | $18.73B | $16.53B | $17.63B | — |
| Change in working capital | — | $251.00B | -$39.33B | $21.94B | -$33.70B | $2.87B | — |
| Operating cash flow | $127.60M | $74.53B | $373.25B | $378.23B | $215.40M | — | -99.8% |
| Capital expenditure | — | -$64.39B | -$222.37B | -$52.83B | -$75.07B | -$92.72B | — |
| Investing cash flow | -$87.70M | -$58.02B | -$229.80B | -$48.13B | -$33.20M | — | +99.8% |
| Share buybacks | — | $0 | $0 | $0 | -$51.60B | -$49.98B | — |
| Dividends paid | — | -$8.79B | -$149.03B | -$8.79B | -$145.29B | -$9.74B | — |
| Financing cash flow | -$180.30M | -$77.49B | -$192.45B | -$11.98B | -$214.90M | — | +99.8% |
| Free cash flow | $127.60M | $10.13B | $150.88B | $325.40B | $215.40M | — | -98.7% |
| End cash position | $461.00M | $595.05B | $654.94B | $681.49B | $350.00M | — | -99.9% |
Options analytics
Put / call volume
0.13
Call-heavy session
Put / call open interest
0.07
Positioning, not flow
Max pain
2.50
-86.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
218
Contracts, this expiry
Put volume
29
Contracts, this expiry
Heaviest call OI
25.00
8 contracts
Heaviest put OI
20.00
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $1.15T | +3.6% |
| Next quarter | — | — | $1.22T | +2.7% |
| Current year | 149.59 | 2 | $4.70T | +694.6% |
| Next year | 138.53 | 1 | $4.79T | +1.8% |
Analyst targets & ownership
Mean target$21.97
High target$22.89
Low target$20.97
Implied upside19.58%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy0 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders0.07%
Held by institutions3.31%
Institutions holding449
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
18.31
+0.36% from price
SMA 20
18.50
-0.69% from price
SMA 50
18.07
+1.67% from price
SMA 100
17.15
+7.11% from price
SMA 200
17.22
+6.70% from price
EMA 12
18.29
+0.42% from price
EMA 26
18.30
+0.36% from price
EMA 50
18.04
+1.84% from price
RSI (14)
51.5
Neutral
MACD (12,26,9)
-0.01
Hist -0.11
ATR (14)
0.28
1.55% of price
Realised vol 30D
18.3%
Annualised
Bollinger upper
19.28
20, 2σ
Bollinger lower
17.72
20, 2σ
50 / 200 cross
Golden
18.07 vs 17.22
Trend bias
Above 200
+6.70%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.19
Less volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
18.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-20.1%
Peak to trough
Max drawdown 5Y
-26.4%
Peak to trough
ATR 14
0.28
1.55% of price
Beta (reported)
0.10
5Y monthly, from filing
Short interest
Shares short
4.20M
Prior 2.99M
Change vs prior
+40.5%
Shorts adding
% of float
0.13%
Normal
% of shares out
0.13%
Against total outstanding
Days to cover
1.9
Liquid
Float
3.16B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 23 | TD Cowen | MAINTAINED | Outperform | Outperform |
| Apr 4, 23 | TD Cowen | MAINTAINED | — | Outperform |
| Mar 16, 23 | B of A Securities | UPGRADE | Neutral | Buy |
| Jul 19, 22 | Cowen & Co. | UPGRADE | Market Perform | Outperform |
| Oct 7, 21 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Mar 11, 20 | JP Morgan | MAINTAINED | — | Overweight |
| Nov 1, 19 | Cowen & Co. | INITIATED | — | Market Perform |
| Sep 24, 19 | Jefferies | INITIATED | — | Buy |
Dividends & splits
Forward rate$0.62 / yr
Forward yield3.36%
5-year avg yield4.42%
Payout ratio279.89%
Ex-dividend dateMar 31, 2026
Next pay dateJul 6, 2026
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-14
Corporate Changes & Voting Matters
6-K · 2026-08-31
Corporate Changes & Voting Matters
6-K · 2026-08-06
Corporate Changes & Voting Matters
6-K · 2026-07-30
Corporate Changes & Voting Matters
6-K · 2026-07-09
Corporate Changes & Voting Matters
6-K · 2026-07-08
Corporate Changes & Voting Matters
6-K · 2026-06-29
Corporate Changes & Voting Matters
6-K · 2026-06-26
Headlines
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading
MT Newswires · 19h ago
Biopharma's Leapfrog Moment: The Launch of the Digital CMC Consortium
PR Newswire · 2d ago
Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run
Simply Wall St. · 7d ago
Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal
Business Wire · 7d ago
Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative
Simply Wall St. · 7d ago
Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data
Simply Wall St. · 8d ago
Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading
MT Newswires · 8d ago
Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial
MT Newswires · 8d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.